Literature DB >> 1330575

A low molecular weight heparin decreases plasma aldosterone in patients with primary hyperaldosteronism.

N Cailleux1, N Moore, H Levesque, H Courtois, M Godin.   

Abstract

Four patients with primary hyperaldosteronism were treated with nadroparin 4100 or 6150 antiXa IU daily for 4 days. Plasma and urine sodium and potassium, and plasma aldosterone and renin were monitored before, during and after the study. After four days of treatment, and for the following two days, plasma aldosterone was decreased (by a mean of 49% on Day 6), and urinary Na/K was increased (3.7-fold). The direction of the changes was reversed on Day 8. The study has confirmed the effect of low molecular weight heparin on aldosterone, and makes it unlikely that it is related to inhibition of angiotensin II stimulation in these patients, as renin could not be detected in their plasma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330575     DOI: 10.1007/bf01740668

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Low molecular weight heparins and hypoaldosteronism.

Authors:  H Levesque; S Verdier; N Cailleux; M C Elie-Legrand; A Gancel; J P Basuyau; J Y Borg; N Moore; H Courtois
Journal:  BMJ       Date:  1990-06-02

2.  Suppression of aldosterone production by low-dose heparin.

Authors:  R A Sherman; M C Ruddy
Journal:  Am J Nephrol       Date:  1986       Impact factor: 3.754

3.  The effect of heparin on aldosterone secretion and metabolism in primary aldosteronism.

Authors:  H C Ford; R E Bailey
Journal:  Steroids       Date:  1966-01       Impact factor: 2.668

4.  Routine heparin therapy inhibits adrenal aldosterone production.

Authors:  R O'Kelly; F Magee; T J McKenna
Journal:  J Clin Endocrinol Metab       Date:  1983-01       Impact factor: 5.958

5.  Direct effects of heparin on basal and stimulated aldosterone production in rat adrenal glomerulosa cells.

Authors:  S Azukizawa; K Uchida; N Imaizumi; H Hosojima; S Morimoto
Journal:  J Steroid Biochem       Date:  1986-09       Impact factor: 4.292

6.  Heparin-induced hyperkalemia.

Authors:  L Aull; H Chao; K Coy
Journal:  DICP       Date:  1990-03

7.  Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia.

Authors:  M Monreal; E Lafoz; R Salvador; J Roncales; A Navarro
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 8.  Drug-induced hyperkalemia.

Authors:  S P Ponce; A E Jennings; N E Madias; J T Harrington
Journal:  Medicine (Baltimore)       Date:  1985-11       Impact factor: 1.889

9.  Effects of heparin treatments in vivo and in vitro on adrenal angiotensin II receptors and angiotensin II-induced aldosterone production in rats.

Authors:  S Azukizawa; I Iwasaki; T Kigoshi; K Uchida; S Morimoto
Journal:  Acta Endocrinol (Copenh)       Date:  1988-11

10.  Heparin-induced hyperkalemia.

Authors:  T E Edes; E V Sunderrajan
Journal:  Arch Intern Med       Date:  1985-06
View more
  2 in total

1.  Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.

Authors:  Giuseppe Gheno; Leonardo Cinetto; Carmelo Savarino; Sandro Vellar; Maurizio Carraro; Massimo Randon
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

2.  Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels.

Authors:  Girish M Bengalorkar; N Sarala; P N Venkatrathnamma; T N Kumar
Journal:  J Pharmacol Pharmacother       Date:  2011-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.